[
  {
    "ts": "2026-01-22T02:47:03+00:00",
    "headline": "Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best High Yield Stocks to Buy. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to a Buy from Neutral. The firm lifted its price target sharply to $65, from $46. UBS said the biotech and pharma space looks like it’s finally turning a corner after […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-bmy-ubs-turns-024703334.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "6f26c606-9b81-35ee-9b52-aec0539ae607",
      "content": {
        "id": "6f26c606-9b81-35ee-9b52-aec0539ae607",
        "contentType": "STORY",
        "title": "Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best High Yield Stocks to Buy. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to a Buy from Neutral. The firm lifted its price target sharply to $65, from $46. UBS said the biotech and pharma space looks like it’s finally turning a corner after […]",
        "pubDate": "2026-01-22T02:47:03Z",
        "displayTime": "2026-01-22T02:47:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-bmy-ubs-turns-024703334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-bmy-ubs-turns-024703334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "UBS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T12:00:00+00:00",
    "headline": "Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors",
    "summary": "SAN DIEGO, January 22, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (\"Janux\"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th",
    "url": "https://finance.yahoo.com/news/janux-therapeutics-announces-collaboration-exclusive-120000075.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "4d8ced26-a153-3d0a-915c-287044759977",
      "content": {
        "id": "4d8ced26-a153-3d0a-915c-287044759977",
        "contentType": "STORY",
        "title": "Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors",
        "description": "",
        "summary": "SAN DIEGO, January 22, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (\"Janux\"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th",
        "pubDate": "2026-01-22T12:00:00Z",
        "displayTime": "2026-01-22T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/daf4290523b997a63e9102100366faa4",
          "originalWidth": 480,
          "originalHeight": 254,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HRogH_K1aYX8QJOgxLE_qw--~B/aD0yNTQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/daf4290523b997a63e9102100366faa4.cf.webp",
              "width": 480,
              "height": 254,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gzPMS0.0GlWr82FmGWOSEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/daf4290523b997a63e9102100366faa4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/janux-therapeutics-announces-collaboration-exclusive-120000075.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/janux-therapeutics-announces-collaboration-exclusive-120000075.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JANX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T12:00:00+00:00",
    "headline": "Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer",
    "summary": "Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft's suite of radiology solutions Originally published on BMS.com PRINCETON, NJ / ACCESS Newswire / January 22, ...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-collaboration-120000893.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "be32bb3e-10e7-3791-bc20-b5180dce5143",
      "content": {
        "id": "be32bb3e-10e7-3791-bc20-b5180dce5143",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer",
        "description": "",
        "summary": "Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft's suite of radiology solutions Originally published on BMS.com PRINCETON, NJ / ACCESS Newswire / January 22, ...",
        "pubDate": "2026-01-22T12:00:00Z",
        "displayTime": "2026-01-22T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-collaboration-120000893.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-collaboration-120000893.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T14:15:00+00:00",
    "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
    "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
    "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f5fef165-ab14-3534-b7b8-9cc6de40c73d",
      "content": {
        "id": "f5fef165-ab14-3534-b7b8-9cc6de40c73d",
        "contentType": "STORY",
        "title": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
        "description": "",
        "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
        "pubDate": "2026-01-22T14:15:00Z",
        "displayTime": "2026-01-22T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T12:00:00+00:00",
    "headline": "Bristol Myers buys into Janux’s ‘masked’ T cell engagers",
    "summary": "Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.",
    "url": "https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "26dad9d5-bbce-3200-b9fd-bbf72f58a675",
      "content": {
        "id": "26dad9d5-bbce-3200-b9fd-bbf72f58a675",
        "contentType": "STORY",
        "title": "Bristol Myers buys into Janux’s ‘masked’ T cell engagers",
        "description": "",
        "summary": "Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.",
        "pubDate": "2026-01-22T12:00:00Z",
        "displayTime": "2026-01-22T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/eda032169031c39772242e0604484c0d",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Cancer vaccines being developed by Moderna, BioNTech and Gritstone are meant to train the immune system to target proteins unique to a person's tumor.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QpQYC0llPS2.uKk2EPmDZg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/eda032169031c39772242e0604484c0d.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6DCqBhra5G86CUZoEaWH9w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/eda032169031c39772242e0604484c0d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-buys-janux-masked-120000343.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JANX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T18:01:57+00:00",
    "headline": "BMS bets on Janux’s novel solid tumour therapy through $850m deal",
    "summary": "This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.",
    "url": "https://www.pharmaceutical-technology.com/news/bms-janux-therapeutics-850m-solid-tumour-oncology-licensing-deal/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "a981b0d3-f6e2-398d-ba32-029d7b124398",
      "content": {
        "id": "a981b0d3-f6e2-398d-ba32-029d7b124398",
        "contentType": "STORY",
        "title": "BMS bets on Janux’s novel solid tumour therapy through $850m deal",
        "description": "",
        "summary": "This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.",
        "pubDate": "2026-01-22T18:01:57Z",
        "displayTime": "2026-01-22T18:01:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/93e02208414e56a6fd94b874bcd8b876",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "BMS' agreement with Janux Therapeutics marks another step towards the pharma bolstering its therapeutic pipeline amid the looming patent expiries of Opdivo and Eliquis. Image credit: PixelBiss via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4it__9HmQuTfzST7mQeRWw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/93e02208414e56a6fd94b874bcd8b876.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z6T19s98duF7kLWu53fiWQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/93e02208414e56a6fd94b874bcd8b876.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/bms-janux-therapeutics-850m-solid-tumour-oncology-licensing-deal/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bms-bets-janux-novel-solid-180157912.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JANX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]